Coya Therapeutics Inc. (COYA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
Coya Therapeutics, Inc. (COYA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.19 per share a year ago.
Coya Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 David Einhorn Greenlight Capital Re Ltd. | 1.27M | $8.12M | $5.86M | -$2.26M | -27.84% |
 Point72 Asset Management LP Point72 Asset Management LP | 37,681 | $218,549.68 | $167,303.64 | -$51,246.04 | -23.45% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $12 | $13.32 | $1.32 | 11% |
Coya Therapeutics Inc. (COYA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Coya Therapeutics Inc. ever had a stock split?
Coya Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Arun Swaminathan CEO | NASDAQ (CM) Exchange | 22407B108 CUSIP |
| US Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on harnessing the potential of regulatory T cells (Tregs) to treat various diseases. With a rich pipeline of proprietary medicinal products, the company seeks to modulate the function of Tregs through diverse therapeutic modalities, including biologics, exosomes derived from Tregs, and autologous Treg cell therapy. Established in 2020 and based in Houston, Texas, Coya Therapeutics is pioneering efforts in developing treatments for neurodegenerative, autoimmune, and metabolic diseases, leveraging groundbreaking scientific research and strategic collaborations.
Products and Services
- COYA 101: An autologous regulatory T-cell product that has completed a Phase 2a clinical trial for treating Amyotrophic Lateral Sclerosis (ALS). This therapy signifies a direct approach to utilizing Tregs to combat ALS, showcasing the company's dedication to addressing neurodegenerative disorders at their immunological roots.
- COYA 301: A low-dose interleukin 2 Treg-enhancing biologic currently in a Phase 2 clinical trial aimed at treating Frontotemporal Dementia. By modulating Treg activity, COYA 301 represents a novel therapeutic avenue for dementia, reflecting Coya Therapeutics' commitment to pioneering treatments for challenging neurodegenerative conditions.
- COYA 302: A biologic combination designed for subcutaneous administration to enhance Treg function while simultaneously depleting T effector function and activated macrophages. Intended for the treatment of neurodegenerative and autoimmune diseases, COYA 302 points to a novel multimodal strategy in disease management. The development and commercialization of COYA 302 have been undertaken in collaboration with Dr. Reddy's Laboratories SA, marking a significant step towards bringing this investigational therapy to patients with amyotrophic lateral sclerosis.
- COYA 201 and COYA 206: Both are antigen-directed Treg-derived exosome product candidates, with COYA 201 in the preclinical stage and COYA 206 in the discovery stage for the treatment of neurodegenerative, autoimmune, and metabolic diseases. These candidates illustrate Coya Therapeutics' innovative approach to deploying Treg-derived exosomes, offering a new therapeutic modality with potential applications across a broad spectrum of diseases.
